Endometriosis and ovarian cancer

Endometriosis is a common disease (7-15%) in all woman of reproductive age, while the incidence of ovarian cancer (0.72-3.92%) in patients with endometriosis is higher than that in the general population. The coexistence of endometriosis and cancer has been estimated to occur in 0.7-5.0% of all cases with ovarian endometriosis, especially ovarian cancer. Woman with endometriosis have an increased risk for several types of malignancies : overall cancer (RR 1.04-1.20), breast cancer (RR 1.30), ovarian cancer (RR 1.43-1.90), endocrine tumour (RR 1.36), hematologic malignancies (RR 1.40), non-hodgkin lymphoma (RR 1.24), and brain tumour (RR 1.22).

Several reports support the theory that endometrioid epithelial ovarian cancer (EEOC) and Ovarian clear cell carcinoma (OCCC) arise in endometriosis. There are two postulated explanations. First, direct transformation, a transition from benign to malignant epithelium, is often evident. Second, iron released by hemorrhage in the endometrial cysts induces persistent oxidative stress and frequent DNA mutations. Molecular investigations on the transformation of endometriosis to ovarian cancer have attributed it to various genetic mutations.
Endometriosis as a prognostic factor for cancer Survival
Although endometriosis cannot be termed a premalignant condition, epidemiologic, histopathologic, and molecular data suggest that this disease does have malignant potential. An imbalance in local estrogen production regulation and sensitivity to progesterone and local inflammatory response modulation through cytokines and growth factors and multiple other molecular alterations seem to favor the invasion and growth of the disease and its progression to carcinoma. In the future, larger studies will be required to elucidate the biological behavior of the malignant transformation of endometriotic lesions, the histological pattern of disease progression and the genetic alterations which associates the two diseases. In the light of the evidence produced by molecular pathology research and epidemiological studies, modifications in currant diagnostic and treatment options for endometriosis information of cancer prevention strategies are needed to be discussed in order to prevent unnecessary medical interventions but not to miss the diagnosis of cancer.
Vejthani ART Center Phone: +66(0)2734-0000 ext. 4600, 4605
  Thailand Consumers Choice,

Thailand Consumers Choice, known as CC, is a well-known brand. Any brand recognized by CC is a measure of success for it means that their goods and services can be relied on .This particular field is based on the data of Research organization  which are  under the Management of Asian Integrated Media Co.Ltd.CC  has been  widely recognized in Asia Pacific and Europe. Vejthani Hospital has been confirmed by Consumers Choice Award for its Major health care facilities, where public trust and confidence in their Quality of service achieved.



2017© International Hospital, Vejthani Hospital :   1 Ladprao Road 111, Klong-Chan Bangkapi,Bangkok,Thailand 10240
English hotline (+66) 85-223-8888 Russia hotline (+66) 85-230-5555
Arabic   hotline (+66) 84-875-7711 , (+66) 84-875-6677 Ethiopia hot line (+66) 84-751-6222
Bangla   hotline (+66) 85-485-2333 Call Center (+66) 2734-0000
Myanmar hotline (+66) 81-984-5111 Fax. : (+66) 2734-0008

Customer Contact : int_mkt@vejthani.com, cambodia@vejthani.com, bangladesh@vejthani.com
                                myanmar@vejthani.com, ethiopia@vejthani.com, arabic@vejthani.com


Vejthani Hospital
About Us
Our Physicians
Centers & Clinics
Hospital Accreditation
Patient Services
Our Cilent Testimonials
Make Appointment
Overseas Offices
Health Article
Hotels Nearby Vejthani
Contact Us & Location
Site Map